Drug details

Posluma (flotufolastat f 18 injection)

type of Diagnostic Imaging Agents

Posluma (flotufolastat F 18) is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

The drug is often used to treat Prostate cancer .

This drug may have the following side effects:

• diarrhea,
• increased blood pressure, and
• injection site pain.

The following drugs are related to Posluma, either as a replacement or used together:

• Yonsa (abiraterone acetate tablets)
• Erleada (apalutamide tablets)
• Casodex (bicalutamide)
• Jevtana (cabazitaxel injection)
• Taxotere (docetaxel for injection)
• Eligard (leuprolide acetate)
• Xtandi (enzalutamide capsules)
• Zoladex 3.6 (goserelin acetate implant)
• Pluvicto (lutetium lu 177 vipivotide tetraxetan)
• Lynparza (olaparib capsules for oral administration)
• Orgovyx (relugolix tablets)
• Xofigo (radium ra 223 dichloride)